Nuri Braintech

Company Overview

Snapshot

Founded in July 2024 by Dan Rappaport and Miri Polachek, Nuri Braintech operates with 1–10 employees. The company has secured funding across two rounds. In April 2025, embARC Ventures participated in a Pre-Seed funding round.

Business overview

Nuri Braintech is dedicated to transforming care for individuals with severe, treatment-resistant psychiatric conditions. The company has developed the first emotion brain-computer interface (eBCI) for psychiatry, designed to detect, decode, and recalibrate trauma responses at their source. This implantable platform utilizes Deep Brain Recoding (DBR) to personalize neuromodulation protocols to each patient’s neural signature, retraining emotional patterns through native learning mechanisms and adaptive stimulation. Nuri Braintech primarily serves the healthcare industry, focusing on conditions like PTSD, and operates within the Health Tech & Life Sciences sector, specifically in Medical Devices and Medical Treatment & Therapeutics.

Company Intelligence Q&A

What is Nuri Braintech's core technology?

Nuri Braintech has developed the first emotion brain-computer interface (eBCI) for psychiatry. This implantable platform detects and decodes dysfunctional emotional circuits and delivers real-time, closed-loop neuromodulation through Deep Brain Recoding (DBR).

When was Nuri Braintech founded and by whom?

Nuri Braintech was founded in July 2024 by Dan Rappaport and Miri Polachek.

Which investor participated in Nuri Braintech's Pre-Seed funding round?

In April 2025, embARC Ventures participated in Nuri Braintech's Pre-Seed funding round.

What type of non-equity funding did Nuri Braintech receive?

In July 2025, Nuri Braintech secured a grant from the Israel Innovation Authority.

What specific psychiatric condition does Nuri Braintech initially target?

Nuri Braintech's technology initially targets severe, treatment-resistant forms of PTSD, with plans to expand across other psychiatric indications.